ClinicalTrials.gg
CompletedNCT02724644Updated Nov 6, 2017Results posted

EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

A Phase 2 interventional study of COLLAGENASE CLOSTRIDIUM HISTOLYTICUM and Placebo Comparator in Edematous Fibrosclerotic Panniculopathy and Cellulite, sponsored by Endo Pharmaceuticals. Completed at 16 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-06.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
375
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing Microbial Collagenase in Cellulite — none open to participants now, none under way, none of them phase 3. Microbial Collagenase · Cellulite.

Enrollment
4th of 15
375 · median 150
Started
2016
with 1 other
Phase 2
8 of 15
none open now
Registered
3rd of 15
by date
Lead sponsor
14 of 15
Endo Pharmaceuticals

Among the 15 studies testing Microbial Collagenase in Cellulite, this one is the 4th largest by enrollment, is one of 2 that started in 2016, is one of 8 in phase 2, and was the 3rd registered.

Cellulite

71 studies on the registry are indexed under Cellulite; 3 are open to participants now.

Browse Cellulite studies →

Open to participants now

None of the 15 studies testing Microbial Collagenase in Cellulite is open now. The open studies under Cellulite, anywhere →

Where they have run

About Microbial Collagenase

Microbial Collagenase: first FDA approval 1965 (SANTYL), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1 Cellulite study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing Microbial Collagenase in Cellulite as a file.
02

Study summary

The study will evaluate the safety, effectiveness, and immunogenicity of EN3835 in the treatment of adult women with Edematous Fibrosclerotic Panniculopathy (Commonly known as Cellulite).

03

Conditions studied

  • Edematous Fibrosclerotic Panniculopathy
  • Cellulite

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be a female ≥18 years of age
  • At Screening visit, have at least 1 quadrant with:

    • a score of 3 or 4 (moderate or severe) as reported by the subject (PR- PCSS), and
    • a score of 3 or 4 (moderate or severe) as reported by the Investigator (CR-PCSS), and
    • a Hexsel CSS score no greater than 13
  • At Day 1 visit, have an assigned quadrant with:

    • a score of 3 or 4 (moderate or severe) as reported by the subject (PR-PCSS), and
    • a score of 3 or 4 (moderate or severe) as reported by the Investigator (CR-PCSS), and
    • a Hexsel CSS score no greater than 13
  • Be willing to apply sunscreen to the selected treatment quadrant before each exposure to the sun while participating in the study (ie, screening through end of study).
  • Be judged to be in good health, based upon the results of a medical history, physical examination, and laboratory profile at screening
  • Have a negative urine pregnancy test at screening and be using an effective method (eg, abstinence, intrauterine device [IUD], hormonal [estrogen/progestin] contraceptives, or double barrier method) for at least 1 menstrual cycle prior to study enrollment and for the duration of the study; or be menopausal defined as 12 months of amenorrhea in the absence of other biological or physiological causes, as determined by the investigator; or for at least 1 year; or be surgically sterile.
  • Be willing and able to cooperate with the requirements of the study
  • Voluntarily sign and date an agreement approved by the Institutional Review Board/Independent Ethics Committee/Human Research Ethics Committee (IRB/IEC/HREC).
  • Be able to read, complete and understand the Patient Reported Outcomes rating instruments in English

Exclusion criteria

Exclusion Criteria:

  • Has any of the following conditions:

    • Thyroid disease, unless controlled with medication for ≥6 months
    • Uncontrolled diabetes mellitus, as determined by the Investigator
    • Uncontrolled hypertension, as determined by the Investigator
    • Vascular disorder (eg, phlebitis or varicose veins) in area to be treated
    • Cushing's disease and/or use of systemic at a total daily dose greater than 5 mg prednisone (or equivalent)
    • History of lower extremity thrombosis or post-thrombosis syndrome
    • Documented disorder such as lupus erythematosus, rheumatoid arthritis
    • Inflammation or active infection in area to be treated
    • Active cutaneous alteration in area to be treated including rash, eczema, psoriasis or skin cancer
    • History of keloidal scarring or abnormal wound healing
    • Coagulation disorder
    • Taking a medication for chronic anticoagulation (except for ≤150 mg aspirin daily)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
375 participants (actual)

Study arms

  • Experimental
    EN3835 Active

    EN3835 0.84 mg (Collagenase Clostridium Histolyticum). Each subject can receive up to three treatment sessions. Each treatment session will be separated by approximately 21 days.

    Biological: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM

  • Placebo comparator
    EN3835 Placebo

    Placebo

    Biological: Placebo Comparator

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Composite Responders of at Least 2-Level Improvement of Severity

    Percentage of composite responders defined as subjects with an improvement from baseline of at least 2-levels of severity on each, the Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) and Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS), at Day 71 in the ITT population. The CR-PCSS is a photonumeric scale that was used by the Investigator to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). The PR-PCSS is a photonumeric scale that was used by the subjects to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). A 2-level improvement on each scale for example would represent a change from a 4 (severe) to a 2 (mild). In order to be considered a responder a subject needs to have at least a 2-level improvement on both scales.

    Time frame: Baseline, Day 71

Secondary outcomes

  1. Percentage of Composite Responders of at Least 1-Level Improvement of Severity

    Percentage of composite responders defined as subjects with improvement from baseline of at least 1-level of severity on each, the Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) and Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS), at Day 71 in the ITT population. The CR-PCSS is a photonumeric scale that was used by the Investigator to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). The PR-PCSS is a photonumeric scale that was used by the subjects to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). A 1-level improvement on each scale for example would represent a change from a 4 (severe) to a 3 (moderate). In order to be considered a responder a subject needs to have at least a 1-level improvement on both scales.

    Time frame: Baseline, Day 71

  2. CR-PCSS Responder Analysis: 2-Levels of Severity

    Percentage of subjects with improvement from baseline of at least 2-levels of severity on the Investigator-rated Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) at Day 71.The CR-PCSS is a photonumeric scale that was used by the Investigator to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). A 2-level improvement would be for example a change from 4 (severe) to 2 (mild).

    Time frame: Baseline, Day 71

  3. CR-PCSS Responder Analysis: 1-Level of Severity

    Percentage of subjects with improvement from baseline of at least 1-level of severity on the Investigator-rated Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) at Day 71.The CR-PCSS is a photonumeric scale that was used by the investigator to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). A 1-level improvement would be for example a change from 4 (severe) to 3 (moderate).

    Time frame: Baseline, Day 71

  4. CR-PCSS Change From Baseline

    The CR-PCSS is a photonumeric scale that was used by the investigator to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). Change is Day 71 study visit rating minus baseline visit; negative values indicate a lessening in cellulite severity.

    Time frame: Baseline, Day 71

  5. PR-PCSS Responder Analysis: 2-Levels of Severity

    Percentage of subjects with improvement from baseline of at least 2-levels of severity on the subject-rated Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) at Day 71.The PR-PCSS is a photonumeric scale that was used by the subject to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). A 2-level improvement would be for example a change from 4 (severe) to 2 (mild).

    Time frame: Baseline, Day 71

  6. PR-PCSS Responder Analysis: 1-Level of Severity

    Percentage of subjects with improvement from baseline of at least 1-level of severity on the subject-rated Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) at Day 71.The PR-PCSS is a photonumeric scale that was used by the subject to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). A 1-level improvement would be for example a change from 4 (severe) to 3 (moderate).

    Time frame: Baseline, Day 71

  7. PR-PCSS Change From Baseline

    The PR-PCSS is a photonumeric scale that was used by the subjects to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). Change is Day 71 study visit rating minus baseline visit; negative values indicate a lessening in cellulite severity.

    Time frame: Baseline, Day 71

  8. Investigator Assessment of Improvement Based on the Investigator Global Aesthetic Improvement Scale (I-GAIS)

    On Day 71, the Investigator determined the degree of improvement from baseline in the treated area using the 7-point I-GAIS. Ratings could be improved (+1), much improved (+2), or very much improved (+3), or no change (0), or worse (-1), much worse (-2) or very much worse (-3).

    Time frame: Day 71

  9. Subject Assessment of Improvement Based on the Subject Global Aesthetic Improvement Scale (S-GAIS)

    At Day 71, subjects were asked to rate their opinion of the overall improvement of their treated area using the 7-point S-GAIS. Ratings could be improved (+1), much improved (+2), or very much improved (+3), or no change (0), or worse (-1), much worse (-2) or very much worse (-3)

    Time frame: Day 71

  10. Subject Satisfaction Assessment Based on the the Subject Satisfaction Scale

    At Day 71, subjects were asked to rate their satisfaction with cellulite treatment using the 5-point subject satisfaction scale. Ratings could be satisfied (+1), very satisfied (+2), neither satisfied nor dissatisfied (0), or dissatisfied (-1), very dissatisfied (-2).

    Time frame: Day 71

  11. Change in the Hexsel Cellulite Severity Scale (CSS) Total Score

    Investigator used the Hexsel CSS to assess the severity of cellulite. The total score could range from 0 (no cellulite) to 15 (extremely severe cellulite). Negative change in Hexsel CSS total score indicates an improvement in cellulite severity

    Time frame: Baseline, Day 71

07

Results

Posted Nov 6, 2017

Participant flow

Participant flow — Overall Study
MilestoneEN3835 0.84 mgPlacebo
Started189186
Completed168182
Not completed214
Withdrew: Adverse event71
Withdrew: Lost to follow-up62
Withdrew: Withdrawal by subject71
Withdrew: Administrative10

Outcome measures

PrimaryPercentage of Composite Responders of at Least 2-Level Improvement of Severity

Percentage of composite responders defined as subjects with an improvement from baseline of at least 2-levels of severity on each, the Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) and Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS), at Day 71 in the ITT population. The CR-PCSS is a photonumeric scale that was used by the Investigator to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). The PR-PCSS is a photonumeric scale that was used by the subjects to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). A 2-level improvement on each scale for example would represent a change from a 4 (severe) to a 2 (mild). In order to be considered a responder a subject needs to have at least a 2-level improvement on both scales.

Time frame:
Baseline, Day 71
Reported as:
Count of participants · Participants
Percentage of Composite Responders of at Least 2-Level Improvement of Severity
ParticipantsEN3835 0.84 mgPlacebo
Percentage of Composite Responders of at Least 2-Level Improvement of Severity203
SecondaryPercentage of Composite Responders of at Least 1-Level Improvement of Severity

Percentage of composite responders defined as subjects with improvement from baseline of at least 1-level of severity on each, the Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) and Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS), at Day 71 in the ITT population. The CR-PCSS is a photonumeric scale that was used by the Investigator to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). The PR-PCSS is a photonumeric scale that was used by the subjects to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). A 1-level improvement on each scale for example would represent a change from a 4 (severe) to a 3 (moderate). In order to be considered a responder a subject needs to have at least a 1-level improvement on both scales.

Time frame:
Baseline, Day 71
Reported as:
Count of participants · Participants
Percentage of Composite Responders of at Least 1-Level Improvement of Severity
ParticipantsEN3835 0.84 mgPlacebo
Percentage of Composite Responders of at Least 1-Level Improvement of Severity7933
SecondaryCR-PCSS Responder Analysis: 2-Levels of Severity

Percentage of subjects with improvement from baseline of at least 2-levels of severity on the Investigator-rated Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) at Day 71.The CR-PCSS is a photonumeric scale that was used by the Investigator to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). A 2-level improvement would be for example a change from 4 (severe) to 2 (mild).

Time frame:
Baseline, Day 71
Reported as:
Count of participants · Participants
CR-PCSS Responder Analysis: 2-Levels of Severity
ParticipantsEN3835 0.84 mgPlacebo
CR-PCSS Responder Analysis: 2-Levels of Severity329
SecondaryCR-PCSS Responder Analysis: 1-Level of Severity

Percentage of subjects with improvement from baseline of at least 1-level of severity on the Investigator-rated Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) at Day 71.The CR-PCSS is a photonumeric scale that was used by the investigator to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). A 1-level improvement would be for example a change from 4 (severe) to 3 (moderate).

Time frame:
Baseline, Day 71
Reported as:
Count of participants · Participants
CR-PCSS Responder Analysis: 1-Level of Severity
ParticipantsEN3835 0.84 mgPlacebo
CR-PCSS Responder Analysis: 1-Level of Severity9653
SecondaryCR-PCSS Change From Baseline

The CR-PCSS is a photonumeric scale that was used by the investigator to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). Change is Day 71 study visit rating minus baseline visit; negative values indicate a lessening in cellulite severity.

Time frame:
Baseline, Day 71
Reported as:
Mean · units on a scale
CR-PCSS Change From Baseline
units on a scaleEN3835 0.84 mgPlacebo
CR-PCSS Change From Baseline-0.7 ± 0.83-0.3 ± 0.62
SecondaryPR-PCSS Responder Analysis: 2-Levels of Severity

Percentage of subjects with improvement from baseline of at least 2-levels of severity on the subject-rated Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) at Day 71.The PR-PCSS is a photonumeric scale that was used by the subject to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). A 2-level improvement would be for example a change from 4 (severe) to 2 (mild).

Time frame:
Baseline, Day 71
Reported as:
Count of participants · Participants
PR-PCSS Responder Analysis: 2-Levels of Severity
ParticipantsEN3835 0.84 mgPlacebo
PR-PCSS Responder Analysis: 2-Levels of Severity5124
SecondaryPR-PCSS Responder Analysis: 1-Level of Severity

Percentage of subjects with improvement from baseline of at least 1-level of severity on the subject-rated Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) at Day 71.The PR-PCSS is a photonumeric scale that was used by the subject to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). A 1-level improvement would be for example a change from 4 (severe) to 3 (moderate).

Time frame:
Baseline, Day 71
Reported as:
Count of participants · Participants
PR-PCSS Responder Analysis: 1-Level of Severity
ParticipantsEN3835 0.84 mgPlacebo
PR-PCSS Responder Analysis: 1-Level of Severity12895
SecondaryPR-PCSS Change From Baseline

The PR-PCSS is a photonumeric scale that was used by the subjects to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). Change is Day 71 study visit rating minus baseline visit; negative values indicate a lessening in cellulite severity.

Time frame:
Baseline, Day 71
Reported as:
Mean · units on a scale
PR-PCSS Change From Baseline
units on a scaleEN3835 0.84 mgPlacebo
PR-PCSS Change From Baseline-1.0 ± 0.89-0.7 ± 0.79
SecondaryInvestigator Assessment of Improvement Based on the Investigator Global Aesthetic Improvement Scale (I-GAIS)

On Day 71, the Investigator determined the degree of improvement from baseline in the treated area using the 7-point I-GAIS. Ratings could be improved (+1), much improved (+2), or very much improved (+3), or no change (0), or worse (-1), much worse (-2) or very much worse (-3).

Time frame:
Day 71
Reported as:
Count of participants · Participants
Investigator Assessment of Improvement Based on the Investigator Global Aesthetic Improvement Scale (I-GAIS)
ParticipantsEN3835 0.84 mgPlacebo
Very Much Improved (3)62
Much improved (2)4015
Improved (1)6443
No Change( 0)57119
Worse (-1)64
Much worse (-2)20
Very Much Worse (-3)00
Not done21
SecondarySubject Assessment of Improvement Based on the Subject Global Aesthetic Improvement Scale (S-GAIS)

At Day 71, subjects were asked to rate their opinion of the overall improvement of their treated area using the 7-point S-GAIS. Ratings could be improved (+1), much improved (+2), or very much improved (+3), or no change (0), or worse (-1), much worse (-2) or very much worse (-3)

Time frame:
Day 71
Reported as:
Count of participants · Participants
Subject Assessment of Improvement Based on the Subject Global Aesthetic Improvement Scale (S-GAIS)
ParticipantsEN3835 0.84 mgPlacebo
Very Much Improved (3)2111
Much Improved (2)4317
Improved (1)6452
No change (0)3897
Worse (-1)65
Much Worse (-2)30
Very Much Worse (-3)00
Not done22
SecondarySubject Satisfaction Assessment Based on the the Subject Satisfaction Scale

At Day 71, subjects were asked to rate their satisfaction with cellulite treatment using the 5-point subject satisfaction scale. Ratings could be satisfied (+1), very satisfied (+2), neither satisfied nor dissatisfied (0), or dissatisfied (-1), very dissatisfied (-2).

Time frame:
Day 71
Reported as:
Count of participants · Participants
Subject Satisfaction Assessment Based on the the Subject Satisfaction Scale
ParticipantsEN3835 0.84 mgPlacebo
Very Satisfied (2)4125
Satisfied (1)6940
Neither Satisfied nor Dissatisfied (0)4582
Dissatisfied (-1)1118
Very Dissatisfied (-2)916
Not done23
SecondaryChange in the Hexsel Cellulite Severity Scale (CSS) Total Score

Investigator used the Hexsel CSS to assess the severity of cellulite. The total score could range from 0 (no cellulite) to 15 (extremely severe cellulite). Negative change in Hexsel CSS total score indicates an improvement in cellulite severity

Time frame:
Baseline, Day 71
Reported as:
Mean · units on a scale
Change in the Hexsel Cellulite Severity Scale (CSS) Total Score
units on a scaleEN3835 0.84 mgPlacebo
Change in the Hexsel Cellulite Severity Scale (CSS) Total Score-1.7 ± 2.20-0.9 ± 2.00

Adverse events

Collected over Baseline, Day 71. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EN3835 0.84 mg—1/189 (0.5%)148/189 (78.3%)
Placebo—0/186 (0%)30/186 (16.1%)
Most frequent serious events
Most frequent serious events
EventEN3835 0.84 mgPlacebo
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/1890/186
Most frequent other events
Most frequent other events
EventEN3835 0.84 mgPlacebo
Injection site bruisingGeneral disorders142/18925/186
Injection site painGeneral disorders112/18910/186
Injection site noduleGeneral disorders27/1890/186
Injection site pruritusGeneral disorders21/1891/186
Injection site swellingGeneral disorders14/1891/186
Injection site indurationGeneral disorders11/1890/186
Injection site massGeneral disorders10/1891/186

Baseline characteristics

Analysis based on intent-to-treat (ITT) population; all randomized subjects who received at least 1 injection of study medication

Age, Continuous
Age, Continuous(Participants)EN3835 0.84 mgPlaceboTotal
Mean47.2 ± 11.2145.8 ± 11.0246.5 ± 11.13
Age, Customized
Age, Customized(Participants)EN3835 0.84 mgPlaceboTotal
18-<25 years8917
25-34 years182139
35-44 years464793
>=45 years117109226
Sex: Female, Male
Sex: Female, Male(Participants)EN3835 0.84 mgPlaceboTotal
Female189186375
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EN3835 0.84 mgPlaceboTotal
Hispanic or Latino374178
Not Hispanic or Latino152145297
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EN3835 0.84 mgPlaceboTotal
American Indian or Alaska Native112
Asian314
Native Hawaiian or Other Pacific Islander011
Black or African American152641
White167157324
More than one race303
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)EN3835 0.84 mgPlaceboTotal
United States189186375
08

Study locations

16 sites
  • Clinical Testing of Beverly Hills
    Beverly Hills, California 90210, United States
  • Dermatology Specialists, Inc
    Murrieta, California 92562, United States
  • Dermatology Specialists, Inc
    Oceanside, California 92056, United States
  • Dermatology Cosmetic Laser Medical Associates of LaJolla, Inc
    San Diego, California 92121, United States
  • Olympian Clinical Research
    Clearwater, Florida 33756, United States
  • Skin Research Institute LLC
    Coral Gables, Florida 33146, United States
  • Research Institute of the Southeast
    West Palm Beach, Florida 33401, United States
  • Mercy Health Research
    Washington, Missouri 10075, United States
  • Bass Plastic Surgery, PLLC
    New York, New York 10065, United States
  • Sadick Research Group
    New York, New York 10075, United States
  • Dermatology Consulting Services
    High Point, North Carolina 27262, United States
  • Tennessee Clinical Research Center
    Nashville, Tennessee 37215, United States
  • Austin Institute for Clinical Research
    Pflugerville, Texas 78660, United States
  • Charlottesville Medical Research Center LLC
    Charlottesville, Virginia 22911, United States
  • The Education & Research Foundation
    Lynchburg, Virginia 24501, United States
  • Premier Clinical Research
    Spokane, Washington 99202, United States
09

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2016, a primary completion of Sep 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2017, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2016
First posted
Mar 31, 2016
Start
Feb 2016
Primary completionActual
Sep 2016
CompletionActual
Sep 2016
Results first posted
Nov 6, 2017
Last update
Nov 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02724644
Responsible party
Sponsor
First posted
Mar 31, 2016
Start date
Feb 2016
Primary completion
Sep 2016
Completion
Sep 2016
Results posted
Nov 6, 2017
Last update
Nov 6, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Microbial Collagenase

Start the discussion